ATE537825T1 - Immunosuppressive verbindungen und zusammensetzungen - Google Patents

Immunosuppressive verbindungen und zusammensetzungen

Info

Publication number
ATE537825T1
ATE537825T1 AT04752678T AT04752678T ATE537825T1 AT E537825 T1 ATE537825 T1 AT E537825T1 AT 04752678 T AT04752678 T AT 04752678T AT 04752678 T AT04752678 T AT 04752678T AT E537825 T1 ATE537825 T1 AT E537825T1
Authority
AT
Austria
Prior art keywords
compositions
immunosuppressive compounds
diseases
immunosuppressant
prevention
Prior art date
Application number
AT04752678T
Other languages
English (en)
Inventor
Thomas Marsilje
Nathanael Gray
Tao Jiang
Wenshuo Lu
Shifeng Pan
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Application granted granted Critical
Publication of ATE537825T1 publication Critical patent/ATE537825T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT04752678T 2003-05-19 2004-05-19 Immunosuppressive verbindungen und zusammensetzungen ATE537825T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47193103P 2003-05-19 2003-05-19
PCT/US2004/015701 WO2004103309A2 (en) 2003-05-19 2004-05-19 Immunosuppressant compounds and compositions

Publications (1)

Publication Number Publication Date
ATE537825T1 true ATE537825T1 (de) 2012-01-15

Family

ID=33476902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04752678T ATE537825T1 (de) 2003-05-19 2004-05-19 Immunosuppressive verbindungen und zusammensetzungen

Country Status (17)

Country Link
US (2) US7060697B2 (de)
EP (1) EP1638551B1 (de)
JP (1) JP4575920B2 (de)
CN (4) CN1816544B (de)
AT (1) ATE537825T1 (de)
AU (2) AU2004240649A1 (de)
BR (1) BRPI0410454A (de)
CA (1) CA2524054C (de)
CY (1) CY1112505T1 (de)
DK (1) DK1638551T3 (de)
ES (1) ES2379169T3 (de)
MX (1) MXPA05012459A (de)
PL (1) PL1638551T3 (de)
PT (1) PT1638551E (de)
SI (1) SI1638551T1 (de)
WO (1) WO2004103309A2 (de)
ZA (1) ZA200508203B (de)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003259296A1 (en) * 2002-07-30 2004-02-16 University Of Virginia Patent Foundation Compounds active in spinigosine 1-phosphate signaling
AU2004268455B2 (en) * 2003-08-29 2009-12-17 Ono Pharmaceutical Co., Ltd. Compound capable of binding S1P receptor and pharmaceutical use thereof
WO2005041899A2 (en) * 2003-11-03 2005-05-12 University Of Virginia Patent Foundation Orally available sphingosine 1-phosphate receptor agonists and antagonists
TW200538433A (en) * 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
WO2005082841A1 (en) * 2004-02-24 2005-09-09 Irm Llc Immunosuppressant compounds and compositions
PT1772145E (pt) 2004-07-16 2011-05-27 Kyorin Seiyaku Kk Processo de utiliza??o eficaz de um medicamento e processo respeitante ? preven??o de efeitos secund?rios
BRPI0516337A (pt) 2004-10-12 2008-04-29 Kyorin Seiyaku Kk processo para a produção de 2- amino-2-[4-(3-benziloxifeniltio) -2- (clorofenil} etil] - 1,3 - hidrocloreto de propanediol e hidratos dos mesmos e produtos intermerdiários para a produção dos mesmos
MX2007006706A (es) * 2004-12-06 2007-10-18 Univ Virginia Analogos de esfingosina 1-fosfato amida de arilo.
AU2005314938B2 (en) * 2004-12-13 2011-06-09 Ono Pharmaceutical Co., Ltd. Aminocarboxylic acid derivative and medicinal use thereof
RU2007133561A (ru) * 2005-02-08 2009-04-20 Новартис АГ (CH) Индукция антилимфоцитарного антитела комбинацией агониста/модулятора рецептора s1p и иммуносупрессивных лекарственных средств
CA2596990A1 (en) 2005-02-14 2006-08-24 University Of Virginia Patent Foundation Sphingosine 1-phosphate agonists comprising cycloalkanes and 5 -membered heterocycles substituted by amino and phenyl groups
CA2605594A1 (en) * 2005-04-22 2006-11-02 Daiichi Sankyo Company, Limited Heterocyclic compound
CA2619101A1 (en) * 2005-08-23 2007-03-01 Irm Llc Immunosuppressant compounds and compositions
PL1932522T3 (pl) * 2005-10-07 2012-09-28 Kyorin Seiyaku Kk Środek terapeutyczny do leczenia choroby wątroby zawierający jako składnik czynny pochodną 2-amino-1,3-propanodiolu
JP2009528274A (ja) * 2006-01-27 2009-08-06 ユニバーシティ オブ バージニア パテント ファンデーション 神経因性疼痛の治療法
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
EP1987013A1 (de) * 2006-02-09 2008-11-05 University Of Virginia Patent Foundation Bicyclische sphingosin-1-phosphat-analoge
EP2058317B1 (de) 2006-08-08 2013-10-16 Kyorin Pharmaceutical Co., Ltd. Aminophosphorsäureesterderivat und s1p-rezeptor-modulator, der dieses als wirkstoff enthält
EP2053038B1 (de) * 2006-08-08 2016-10-05 Kyorin Pharmaceutical Co., Ltd. Aminoalkoholderivat und dieses als wirkstoff enthaltendes immunosuppressivum
JP2010510250A (ja) * 2006-11-21 2010-04-02 ユニバーシティ オブ バージニア パテント ファンデーション スフィンゴシン＝１−燐酸受容体アゴニスト活性を有するヒドリンダンアナログ
CA2669102A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Tetralin analogs having sphingosine 1-phosphate agonist activity
AU2007323557A1 (en) * 2006-11-21 2008-05-29 University Of Virginia Patent Foundation Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
KR101257550B1 (ko) 2007-09-10 2013-04-24 칼시메디카, 인크 세포내 칼슘을 조절하는 화합물
EP2209771A1 (de) * 2007-11-08 2010-07-28 Pfizer, Inc. Cyclobutyl-carboxylsäurederivate
GB0725104D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
GB0725101D0 (en) * 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
US20090298894A1 (en) * 2008-04-21 2009-12-03 Asahi Kasei Pharma Corporation Amino acid compounds
GB0807910D0 (en) * 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
SI2326621T1 (sl) 2008-07-23 2016-10-28 Arena Pharmaceuticals, Inc. Substituirani derivati 1,2,3,4-tetrahidrociklopenta(b)indol-3-il)ocetne kisline, uporabni pri zdravljenju avtoimunskih in vnetnih motenj
SI2307007T1 (sl) * 2008-07-23 2014-11-28 Novartis Ag Modulatorji sfingozin 1 fosfatnega receptorja in njihova uporaba za zdravljenje mišičnega vnetja
NZ591001A (en) 2008-08-27 2012-11-30 Arena Pharm Inc Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
CN102256969A (zh) 2008-08-27 2011-11-23 钙医学公司 调节胞内钙的化合物
CN102186845B (zh) * 2008-10-17 2016-09-07 阿卡制药有限公司 S1p受体调节剂以及它们的用途
JP2012512884A (ja) * 2008-12-18 2012-06-07 ノバルティス アーゲー １−（４−｛１−［（ｅ）−４−シクロヘキシル−３−トリフルオロメチル−ベンジルオキシイミノ］−エチル｝−２−エチル−ベンジル）−アゼチジン−３−カルボン酸の新規の多形相
CA2747558A1 (en) * 2008-12-18 2010-07-15 Novartis Ag New salts
EP2376484B1 (de) * 2008-12-18 2015-04-22 Merck Serono S.A. Oxadiazol-fusionierte heterozyklische derivate zur behandlung von multipler sklerose
IN2012DN00754A (de) 2009-08-04 2015-06-19 Amira Pharmaceuticals Inc
UA107360C2 (en) * 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
JP2013512243A (ja) * 2009-11-24 2013-04-11 アラーガン インコーポレイテッド 治療的有用性を有する受容体調節物質としての新規化合物
TWI517851B (zh) * 2010-01-13 2016-01-21 賽諾菲阿凡提斯公司 含２，５，７－經取代唑并嘧啶環之雜環羧酸衍生物
AR079981A1 (es) * 2010-01-13 2012-03-07 Sanofi Aventis Derivados de acido carboxilico que comprenden un anillo de oxoazolopirimidina 2,5,7- sustituido
UY33179A (es) * 2010-01-14 2011-08-31 Sanofi Aventis Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2,5-sustituido.
CA2804128C (en) * 2010-01-14 2017-12-12 Sanofi Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring
CA2784565C (en) * 2010-01-14 2018-03-13 Sanofi 2,5-substituted oxazolopyrimidine derivatives
SG10201500639TA (en) 2010-01-27 2015-03-30 Arena Pharm Inc Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN105503882B (zh) 2010-03-03 2019-07-05 艾尼纳制药公司 制备s1p1受体调节剂及其晶体形式的方法
JP5735634B2 (ja) 2010-04-23 2015-06-17 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物
CA2797533A1 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
PT2563776T (pt) 2010-04-27 2016-09-19 Calcimedica Inc Compostos que modulam o cálcio intracelular
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP5869579B2 (ja) 2010-09-24 2016-02-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換オキサジアゾール化合物およびそれらのｓ１ｐ１アゴニストとしての使用
WO2012074926A1 (en) * 2010-12-03 2012-06-07 Allergan, Inc. Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
CN103354742A (zh) * 2010-12-03 2013-10-16 阿勒根公司 作为鞘氨醇1-磷酸(s1p)受体调节剂的新型肟氮杂环丁烷衍生物
ES2674174T3 (es) 2010-12-07 2018-06-27 Bristol-Myers Squibb Company Antagonista de LPA1 policíclico y usos del mismo
BR112013014019A2 (pt) 2010-12-07 2016-09-13 Amira Pharmaceuticals Inc antagonistas do receptor do ácido lisofosfatídico e seus usos
ES2772258T3 (es) * 2011-02-07 2020-07-07 Biogen Ma Inc Agentes moduladores de S1P
EP2694496A1 (de) 2011-04-05 2014-02-12 Amira Pharmaceuticals, Inc. 3-oder 5 - biphenyl- 4 - ylisoxazol -basierte verbindungen zur behandlung von fibrose, schmerzen, krebs, atemwegserkrankungen, allergien, des nervensystems oder von kardiovaskulären erkrankungen
JP2014511878A (ja) * 2011-04-14 2014-05-19 アラーガン インコーポレイテッド スフィンゴシン−１リン酸受容体調節剤としてのフェニル二環式メチルアミン誘導体
US8580816B2 (en) * 2011-07-07 2013-11-12 Sanofi Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring
US8735402B2 (en) * 2011-07-07 2014-05-27 Sanofi Cycloalkyloxycarboxylic acid derivatives
MX2014004813A (es) * 2011-10-21 2014-05-20 Novartis Ag Regimen de dosificacion para un modulador o agonista del receptor s1p.
AU2013214103B2 (en) * 2012-02-03 2015-12-17 Novartis Ag Process for preparing N-(4-cyclohexyl-3-trifluoromethyl-benzyloxy)-acetimidic acid ethyl ester
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2012397435B2 (en) 2012-12-21 2017-03-30 National Institutes For Quantum And Radiological Science And Technology Novel compound for imaging TAU protein accumulated in the brain
US8957061B2 (en) 2013-02-13 2015-02-17 Allergan, Inc. Azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators
EP2990055B1 (de) 2013-04-26 2019-06-05 Kyoto University Sphingosine-1-phosphate rezeptor 1 agonist enthaltende zusammensetzung zur hemmung von hirnaneurysm entstehung und/oder vergrösserung oder zur verkleinerung dieses
CN103408501B (zh) * 2013-08-14 2016-03-09 合肥医工医药有限公司 苄基嘧啶衍生物、其制备方法及其医药用途
EP3046909A4 (de) 2013-09-17 2017-03-29 Pharmakea, Inc. Heterocyclische vinyl-autotaxin-hemmerverbindungen
JP2016530209A (ja) 2013-09-17 2016-09-29 ファーマケア，インク． ビニルオートタキシン阻害剤化合物
WO2015048301A1 (en) 2013-09-26 2015-04-02 Pharmakea, Inc. Autotaxin inhibitor compounds
KR102367876B1 (ko) 2013-11-22 2022-02-24 사브레 테라퓨틱스 엘엘씨 오토탁신 억제제 화합물
UA121309C2 (uk) 2014-02-03 2020-05-12 Вітае Фармасьютікалс, Ллс Дигідропіролопіридинові інгібітори ror-гамма
BR112017007460A2 (pt) 2014-10-14 2017-12-19 Vitae Pharmaceuticals Inc inibidores de di-hidropirrolopiridina de ror-gama
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
CN116850181A (zh) 2015-01-06 2023-10-10 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
EP3265456B1 (de) 2015-03-06 2020-11-18 Pharmakea, Inc. Fluorierte lysyloxidase-like-2-inhibitoren und verwendungen davon
JP6873919B2 (ja) 2015-05-27 2021-05-19 セイバー セラピューティクス エルエルシー オートタキシン阻害剤とその使用
AU2016284162A1 (en) 2015-06-22 2018-02-01 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(Compound1) for use in SIP1 receptor-associated disorders
ES2856931T3 (es) 2015-08-05 2021-09-28 Vitae Pharmaceuticals Llc Moduladores de ROR-gamma
EP3341369A1 (de) * 2015-08-28 2018-07-04 AbbVie Inc. Kondensierte heterocyclische verbindungen als s1p-modulatoren
MX385332B (es) 2015-11-20 2025-03-18 Vitae Pharmaceuticals Llc Moduladores de ror-gamma.
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
MX2018015352A (es) * 2016-06-10 2019-03-28 Io Therapeutics Inc Subtipos de receptores y compuestos retinoides y rexinoides de funcion selectiva combinados con moduladores inmunitarios para inmunoterapia contra el cancer.
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10774069B2 (en) 2016-09-07 2020-09-15 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
WO2018048942A1 (en) 2016-09-07 2018-03-15 Pharmakea, Inc. Uses of a lysyl oxidase-like 2 inhibitor
AU2018220521A1 (en) 2017-02-16 2019-09-05 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
CA3053416A1 (en) 2017-02-16 2018-08-23 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
CN111225914B (zh) 2017-07-24 2022-10-11 生命医药有限责任公司 RORγ的抑制剂
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CA3099318C (en) 2018-05-09 2024-02-13 Aprinoia Therapeutics Inc. Heteroaryl compounds and uses thereof
WO2019236757A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN110776450B (zh) * 2018-07-27 2022-09-27 广东东阳光药业有限公司 一种辛波莫德晶型及其制备方法
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
CN111630029B (zh) * 2018-12-06 2021-04-30 上海济煜医药科技有限公司 作为免疫调节剂的化合物及其制备方法和应用
EP3892616A4 (de) * 2018-12-06 2022-07-27 Shanghai Jemincare Pharmaceuticals Co., Ltd. Aromatisches ringderivat als immunoregulation sowie herstellungsverfahren und anwendung eines aromatischen ringderivats
CN111484434A (zh) * 2019-01-29 2020-08-04 东莞市东阳光仿制药研发有限公司 一种辛波莫德晶型及其制备方法
WO2020173346A1 (zh) * 2019-02-25 2020-09-03 广东东阳光药业有限公司 一种辛波莫德的制备方法
EP4058065A4 (de) 2019-11-13 2023-05-03 Aprinoia Therapeutics Limited Verbindungen zum abbau von tau-protein-aggregaten und deren verwendungen
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
CN119776509A (zh) * 2023-10-08 2025-04-08 华东师范大学 Ndufa10基因和S1pr4基因突变在肌病诊断、预测和治疗中的用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH540247A (de) * 1967-04-21 1973-09-28 Ciba Geigy Ag Verfahren zur Herstellung von heterocyclischen, Asthylendoppelbindungen enthaltenden Verbindungen
IL109161A0 (en) * 1993-03-31 1994-06-24 Cell Therapeutics Inc Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
CA2198242A1 (en) * 1994-08-24 1996-02-29 Eli Lilly And Company Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists
US6110922A (en) * 1998-12-29 2000-08-29 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
US20040235794A1 (en) * 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
WO2003037271A2 (en) * 2001-10-30 2003-05-08 Millennium Pharmaceuticals,Inc. Compounds, pharmaceutical compositions and methods of use therefor
AU2002361430B2 (en) * 2001-12-14 2007-09-13 Zentaris Gmbh Tetrahydrocarbozole derivatives as ligands for G-protein coupled receptors (GPCR)
WO2003062252A1 (en) * 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
DE10207844A1 (de) * 2002-02-15 2003-09-04 Schering Ag 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
HRP20040952A2 (en) * 2002-04-26 2005-06-30 F. Hoffmann - La Roche Ag Isoquinoline derivatives
JP2007186422A (ja) * 2004-01-28 2007-07-26 Astellas Pharma Inc アリールスルフィド誘導体

Also Published As

Publication number Publication date
CY1112505T1 (el) 2015-12-09
CN1787817A (zh) 2006-06-14
EP1638551A4 (de) 2008-12-31
CN1791395B (zh) 2012-09-26
CA2524054C (en) 2012-04-24
CN1787817B (zh) 2011-09-07
CN1816544A (zh) 2006-08-09
CN1791592B (zh) 2012-07-04
CN1816544B (zh) 2011-06-08
WO2004103309A2 (en) 2004-12-02
CA2524054A1 (en) 2004-12-02
AU2008203088A1 (en) 2008-08-07
DK1638551T3 (da) 2012-04-02
ZA200508203B (en) 2007-02-28
JP4575920B2 (ja) 2010-11-04
JP2006528987A (ja) 2006-12-28
PT1638551E (pt) 2012-03-28
US7060697B2 (en) 2006-06-13
US7462629B2 (en) 2008-12-09
SI1638551T1 (sl) 2012-04-30
EP1638551A2 (de) 2006-03-29
HK1090559A1 (en) 2006-12-29
BRPI0410454A (pt) 2006-06-13
MXPA05012459A (es) 2006-02-22
WO2004103309A3 (en) 2005-03-03
US20050014724A1 (en) 2005-01-20
US20050009786A1 (en) 2005-01-13
EP1638551B1 (de) 2011-12-21
PL1638551T3 (pl) 2012-05-31
CN1791592A (zh) 2006-06-21
CN1791395A (zh) 2006-06-21
AU2004240649A1 (en) 2004-12-02
ES2379169T3 (es) 2012-04-23

Similar Documents

Publication Publication Date Title
ATE537825T1 (de) Immunosuppressive verbindungen und zusammensetzungen
TW200505442A (en) Immunosuppressant compounds and compositions
TNSN05294A1 (en) Immunosuppressant compounds and compositions
WO2004113330A8 (en) Immunosuppressant compounds and compositions
WO2005082089A3 (en) Immunosuppressant compounds and compositions
WO2004071442A3 (en) Novel bicyclic compounds and compositions
TW200700068A (en) Phthalazine, aza-and diaza-phthalazine compounds and methods of use
IL190654A (en) Methods of Methyl-Sulfonamido-Propanamido, Processes for Preparation and Medicines Containing Them
ATE384050T1 (de) Benzazepinderivate als histamin-h3-antagonisten
ATE549311T1 (de) Amino-propanolderivative als modulatoren des sphingosin-1-phosphat-rezeptors
TW200612905A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
TW200611702A (en) Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
ATE433966T1 (de) Methylendipiperidinderivate
ATE478863T1 (de) Heterotetracyclische verbindungen als tpo- mimetica
FR2872165B1 (fr) Nouveaux derives de pyrimido-benzimidazole
MX2007006754A (es) Derivados de indenilo y uso de los mismos para el tratamiento de trastornos neurologicos.
ATE467636T1 (de) Pyrazoloä3 , 4-düazepinderivate als histamin-h3- antagonisten
TW200517382A (en) Imidazole derivatives
ES2333026T3 (es) Derivados de ciclohexil-1,4-diamina sustituidos.
ATE524463T1 (de) 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung
ATE417042T1 (de) Substituierte 2,5-diaminomethyl-1h-pyrrole
UA84701C2 (ru) Замещенные индолы, способ их получения, их использования
TW200621255A (en) Novel compounds